STOK Stoke Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1623526 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-86.3%
TTM net income YoY-699.5%
TTM EPS YoY-655.9%
Revenue 3-yr CAGR45.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-913.1%
Net margin-862.1%
FCF margin-764.7%
EBITDA margin-906.9%
Returns
ROE-73.6%
ROA-63.4%
ROIC (approx.)-86.6%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.24x
Interest coverage-4,088.90x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-8.6%
Payout ratio—
Capex / revenue19.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $184.42M | $36.55M | $8.78M | $12.40M | — |
| R&D expense | $137.92M | $89.13M | $82.23M | $77.84M | $54.17M |
| SG&A expense | $67.09M | $48.79M | $41.32M | $38.92M | $31.90M |
| Operating income | -$20.59M | -$101.37M | -$114.77M | -$104.36M | -$86.06M |
| Interest expense | $9,000 | $26,000 | $49,000 | — | — |
| Income tax | $0 | — | — | — | — |
| Net income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | -$85.81M |
| EBITDA | -$18.82M | -$99.19M | -$112.30M | -$102.81M | -$85.09M |
| EPS (basic) | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| EPS (diluted) | -0.12 | -1.65 | -2.38 | -2.60 | -2.34 |
| Weighted avg. shares (diluted) | 59.22M | 54.01M | 43.99M | 38.90M | 36.74M |
| Balance sheet | |||||
| Cash & equivalents | $84.22M | $127.98M | $191.44M | $113.56M | $144.90M |
| Short-term investments | $200.45M | $88.92M | $9.95M | $116.04M | $74.92M |
| Receivables | $5.94M | $1.67M | — | — | — |
| Current assets | $305.70M | $232.76M | $215.34M | $244.07M | $229.22M |
| PP&E, net | $3.15M | $3.91M | $5.82M | $6.67M | $4.14M |
| Total assets | $418.43M | $271.56M | $228.34M | $256.07M | $238.87M |
| Current liabilities | $57.88M | $40.06M | $30.82M | $31.39M | $17.14M |
| Total liabilities | $65.98M | $42.53M | $68.78M | $71.22M | $21.09M |
| Shareholders' equity | $352.46M | $229.02M | $159.56M | $184.85M | $217.78M |
| Shares outstanding | 58.92M | 54.03M | 45.92M | 39.44M | 36.90M |
| Cash flow statement | |||||
| Operating cash flow | $45.59M | -$86.85M | -$81.07M | -$31.87M | -$66.91M |
| Capital expenditure | $670,000 | $203,000 | $1.62M | $3.96M | $1.20M |
| Free cash flow | $44.91M | -$87.05M | -$82.68M | -$35.83M | -$68.11M |
| Investing cash flow | -$186.81M | -$107.47M | $105.95M | -$45.88M | -$76.43M |
| Financing cash flow | $97.39M | $131.09M | $53.01M | $46.41M | $1.28M |
| Depreciation & amortization | $1.77M | $2.18M | $2.47M | $1.55M | $974,000 |
| Stock-based compensation | $32.24M | $27.47M | $25.26M | $22.85M | $16.45M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.